· Published by Health Canada · Official notice
This is duplicated text of a letter from Amgen Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
April 10, 2014
Dear Health Care Professional:
Subject: Neupogen® (filgrastim) is associated with a risk of Capillary Leak Syndrome in patients with cancer and in healthy donors. Neulasta® (pegfilgrastim) is associated with a risk of Capillary Leak Syndrome in patients with cancer.
Amgen Canada Inc., in consultation with Health Canada, would like to inform you of important new safety information concerning the risk of Capillary Leak Syndrome (CLS) associated with the granulocyte colony stimulating factors (G-CSF) NEUPOGEN and NEULASTA.
NEUPOGEN is indicated to:
NEULASTA is indicated to:
Literature and post-marketing cases of Capillary Leak Syndrome (CLS) have been reported uncommonly in patients undergoing chemotherapy and donors undergoing peripheral blood progenitor cell mobilization who were receiving G-CSFs. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis.
The NEUPOGEN AND NEULASTA Product Monographs are being updated to reflect this new safety information.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious Capillary Leak Syndrome or other serious or unexpected adverse reactions in patients receiving NEUPOGEN or NEULASTA should be reported to Amgen Canada Inc. or Health Canada.
The revised Product Monographs may be accessed on the Health Canada Web site, or on www.amgen.ca.
Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, Ontario L5N 0A4
Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655
Safety e-mail: safetycanada@amgen.com
To correct your mailing address or fax number, contact Amgen Canada Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Clive Ward-Able, MD
Executive Medical Director
AMGEN Canada Inc.